PULMATRIX, INC. Capital Expenditures Incurred but Not yet Paid
PULMATRIX, INC. (PULM) reported Capital Expenditures Incurred but Not yet Paid of $244.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-05-15
- PULMATRIX, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $244.00K.
- PULMATRIX, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was -$275.00K.
- PULMATRIX, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $614.00K.
- PULMATRIX, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $389.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-03-31 | $244.00K 10-Q · filed 2025-05-15 | -$31.00K derived: sum of 2 quarters · filed 2025-05-15 | $583.00K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $339.00K derived: sum of 2 quarters · filed 2025-03-21 | $389.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | $614.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $664.00K 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $50.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |